Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The original fixed-combination renal cutoff is retained for explicit comparison with current labeling.
Check source scope before reading a dose
Abacavir / lamivudine - NIH adult HIV guidance
Product / population
NIH adult/adolescent HIV treatment; explicitly qualified fixed-dose-combination exception.
Renal method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
EPZICOM: label restriction versus limited-evidence panel practice
The selected label does not recommend the fixed-dose combination below CrCl 30. NIH describes some panel members retaining full-dose lamivudine there but explicitly states that evidence is insufficient.
What to reconcile: Preserve the evidence qualification and obtain HIV-specialist or institutional adjudication. Do not present that exception as a new label-approved dose.
NIH / HHS Adult and Adolescent Antiretroviral Guidelines Panel · NIH adult/adolescent HIV treatment; explicitly qualified fixed-dose-combination exception.
Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
ABC/3TC is not FDA-recommended below CrCl 30 mL/min because of lamivudine. NIH notes insufficient evidence for or against full-dose lamivudine below 30, although some Panel members retain full-dose therapy to preserve the fixed-dose combination. This is a limited-evidence professional practice, not a new label-approved regimen.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.